United Therapeutics (UTHR) Common Equity (2009 - 2026)

United Therapeutics has disclosed Common Equity across 18 years of filings, most recently posting $5.9 billion for Q1 2026.

• Common Equity for Q1 2026 came in at $5.9 billion, down 13.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.9 billion (down 13.31% YoY), and the FY2025 annual result was $7.1 billion, up 10.12% from the prior year.
• Common Equity came in at $5.9 billion for Q1 2026 at United Therapeutics, down from $7.1 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $7.2 billion in Q2 2025 to a low of $4.2 billion in Q1 2022.
• The 5-year median for Common Equity is $5.7 billion (2023), against an average of $5.7 billion.
• Across the five-year window, Common Equity rose 27.52% in 2025 and retreated 13.31% in 2026, its largest moves.
• United Therapeutics' Common Equity stood at $4.8 billion in 2022, then gained by 24.77% to $6.0 billion in 2023, then increased by 7.67% to $6.4 billion in 2024, then advanced by 10.12% to $7.1 billion in 2025, then decreased by 16.84% to $5.9 billion in 2026.
• The last three Common Equity figures came in at $5.9 billion (Q1 2026), $7.1 billion (Q4 2025), and $6.6 billion (Q3 2025), per Business Quant data.